Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$27,000.00
Identifying tumor heterogeneity and phenotypic plasticity at the single-cell level in response to drugs in high-grade serous ovarian cancer
FY 2024-25
Summary
Ovarian cancer is a serious disease, with survival rates remaining low in Canada. High-grade serous ovarian cancer (HGSOC) is the most common and deadly type, partly because its tumors have unstable DNA, making them hard to treat. However, this instability can also be a weakness: about half of these tumors cant repair their DNA properly, allowing a class of drugs called PARP inhibitors (PARPi) to target them effectively. These drugs have shown promise in slowing disease progression when used after initial chemotherapy. Despite these advances, many patients relapse because HGSOC tumors are highly diverse. They consist of different groups of cancer cells, or clones, each with unique mutations and characteristics. These differences make it easier for the cancer to develop resistance to treatments. Current therapies typically start with chemotherapy followed by PARPi, but it unclear if this order is the best approach. Using advanced tools to study individual tumor cells could help us understand how treatments affect cancer and how resistance develops. This project aims to explore how the order of chemotherapy and PARPi affects treatment resistance and tumor progression. Mouse models grown from patient tumors will be used to compare the outcomes of two approaches: chemotherapy first, then PARPi, versus starting with PARPi followed by chemotherapy. Tumor models that resist PARPi will also be created to study how resistance occurs. By analyzing individual cells from these tumors, this project will identify clues that predict treatment response or resistance. The findings could help develop better strategies to treat resistant ovarian cancer and improve outcomes for patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530214
Name
Lam Paak Long Goldman
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying tumor heterogeneity and phenotypic plasticity at the single-cell level in response to drugs in high-grade serous ovarian cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical Drug Treatment; High-Grade Serous Ovarian Cancer; Pdx Models; Single-Cell Sequencing; Translational Research
Abstract
Ovarian cancer is a serious disease, with survival rates remaining low in Canada. High-grade serous ovarian cancer (HGSOC) is the most common and deadly type, partly because its tumors have unstable DNA, making them hard to treat. However, this instability can also be a weakness: about half of these tumors cant repair their DNA properly, allowing a class of drugs called PARP inhibitors (PARPi) to target them effectively. These drugs have shown promise in slowing disease progression when used after initial chemotherapy. Despite these advances, many patients relapse because HGSOC tumors are highly diverse. They consist of different groups of cancer cells, or clones, each with unique mutations and characteristics. These differences make it easier for the cancer to develop resistance to treatments. Current therapies typically start with chemotherapy followed by PARPi, but it unclear if this order is the best approach. Using advanced tools to study individual tumor cells could help us understand how treatments affect cancer and how resistance develops. This project aims to explore how the order of chemotherapy and PARPi affects treatment resistance and tumor progression. Mouse models grown from patient tumors will be used to compare the outcomes of two approaches: chemotherapy first, then PARPi, versus starting with PARPi followed by chemotherapy. Tumor models that resist PARPi will also be created to study how resistance occurs. By analyzing individual cells from these tumors, this project will identify clues that predict treatment response or resistance. The findings could help develop better strategies to treat resistant ovarian cancer and improve outcomes for patients.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lam, Paak Long Goldman
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~